NCT05840861

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 59 (estimated)
• Sponsor: Central South University · Academic / Other
• Sex: All
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

Evidence suggests that mGLUR5 availability may play a key role in the biology of mood disorders. This study aimed to investigate the changes in metabotropic glutamate receptor 5 (mGLUR5) availability and clinical symptoms in patients with MDD and bipolar disorder(BD) after two months of vortioxetine treatment. The investigators hypothesized that patients with MDD and BP have abnormal mGluR5 availability in certain brain regions, and baseline mGLUR5 availability can predict prognosis the prognosis of MDD and BD. fMRI and NODDI are also used to evaluate the function or neurite condition at baseline and 8 week

Conditions

• Major Depressive Disorder
• Bipolar Disorder

Interventions

Type	Name	Description
DRUG	Vortioxetine	All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.
DRUG	Quetiapine	All patients with bipolar disorder will receive 50mg of Quetiapine at day 1, 100mg of Quetiapine at day 2, 200mg of Quetiapine at day 3, and 400mg of Quetiapine per day since day 4.

Timeline

• Start date: 2020-11-05
• Primary completion: 2023-08-21
• Completion: 2023-09-05
• First posted: 2023-05-03
• Last updated: 2023-08-14

Locations

1 site across 1 country: China